The FDA labeled Novo Nordisk Wegovy TV ad as "misleading," stating it falsely implies the pill is better than other weight loss treatments. The agency argued phrases like "live lighter" overstated benefits, violating federal regulations. Novo shares, which were up over 8%, pared gains to 4% following the news. The company has 15 days to respond to the FDA's letter.